These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 30604371)

  • 1. Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse.
    Iborra M; Herreras J; Boscá-Watts MM; Cortés X; Trejo G; Cerrillo E; Hervás D; Mínguez M; Beltrán B; Nos P
    Dig Dis Sci; 2019 Jun; 64(6):1612-1621. PubMed ID: 30604371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal.
    Cassinotti A; Actis GC; Duca P; Massari A; Colombo E; Gai E; Annese V; D'Albasio G; Manes G; Travis S; Porro GB; Ardizzone S
    Am J Gastroenterol; 2009 Nov; 104(11):2760-7. PubMed ID: 19623172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poor Drug Sustainability in Inflammatory Bowel Disease Patients in Clinical Remission on Thiopurine Monotherapy.
    Balram B; Lubov J; Theoret Y; Afif W; Bitton A; Wild G; Lakatos PL; Bessissow T
    Dig Dis Sci; 2021 May; 66(5):1650-1657. PubMed ID: 32591969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis.
    Khan KJ; Dubinsky MC; Ford AC; Ullman TA; Talley NJ; Moayyedi P
    Am J Gastroenterol; 2011 Apr; 106(4):630-42. PubMed ID: 21407186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis.
    Mantzaris GJ; Sfakianakis M; Archavlis E; Petraki K; Christidou A; Karagiannidis A; Triadaphyllou G
    Am J Gastroenterol; 2004 Jun; 99(6):1122-8. PubMed ID: 15180735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients.
    Kennedy NA; Kalla R; Warner B; Gambles CJ; Musy R; Reynolds S; Dattani R; Nayee H; Felwick R; Harris R; Marriott S; Senanayake SM; Lamb CA; Al-Hilou H; Gaya DR; Irving PM; Mansfield J; Parkes M; Ahmad T; Cummings JR; Arnott ID; Satsangi J; Lobo AJ; Smith M; Lindsay JO; Lees CW
    Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1313-23. PubMed ID: 25284134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive Monitoring After Azathioprine Withdrawal in Patients With Inflammatory Bowel Disease in Deep Remission.
    Cassinotti A; Corona A; Duca P; Nebuloni M; Maconi G; Fociani P; Ardizzone S
    Clin Gastroenterol Hepatol; 2021 Nov; 19(11):2293-2301.e1. PubMed ID: 34139332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease.
    Chan W; Lynch N; Bampton P; Chang J; Chung A; Florin T; Hetzel DJ; Jakobovits S; Moore G; Pavli P; Radford-Smith G; Thin L; Baraty B; Haifer C; Yau Y; Leong RWL
    Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):735-740. PubMed ID: 29727386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Withdrawal of long-term maintenance treatment with azathioprine tends to increase relapse risk in patients with Crohn's disease.
    Wenzl HH; Primas C; Novacek G; Teml A; Öfferlbauer-Ernst A; Högenauer C; Vogelsang H; Petritsch W; Reinisch W
    Dig Dis Sci; 2015 May; 60(5):1414-23. PubMed ID: 25381202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission.
    Lichtenstein GR; Gordon GL; Zakko S; Murthy U; Sedghi S; Pruitt R; Barrett AC; Bortey E; Paterson C; Forbes WP
    Dig Dis Sci; 2016 Jan; 61(1):221-9. PubMed ID: 26563167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azathioprine is effective in corticosteroid-dependent Asian inflammatory bowel disease patients.
    Thia KT; Li M; Ling KL; Kong SC; Ooi CJ
    Inflamm Bowel Dis; 2011 Mar; 17(3):809-15. PubMed ID: 20645318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases.
    Pariente B; Laharie D
    Aliment Pharmacol Ther; 2014 Aug; 40(4):338-53. PubMed ID: 24957164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
    Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
    Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of sustained combination therapy for at least 6 months with thiopurines and infliximab in patients with ulcerative colitis in clinical remission: a retrospective multicenter French experience.
    Filippi J; Laharie D; Michiels C; Flamand M; Bouguen G; Nancey S; Presles E; Paul S; Schneider S; Hébuterne X; Roblin X
    J Crohns Colitis; 2015 Mar; 9(3):252-8. PubMed ID: 25588386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.
    Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC
    World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice.
    Ampuero J; Rojas-Feria M; Castro-Fernández M; Millán-Lorenzo M; Guerrero-Jiménez P; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Jan; 31(1):112-8. PubMed ID: 26173493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis.
    Hibi T; Naganuma M; Kitahora T; Kinjyo F; Shimoyama T
    J Gastroenterol; 2003; 38(8):740-6. PubMed ID: 14505127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapse rates after withdrawal of thiopurines in patients with inflammatory bowel disease.
    Ranjan MK; Vuyyuru SK; Kante B; Kumar P; Mundhra SK; Golla R; Sharma R; Sahni P; Das P; Makharia G; Kedia S; Ahuja V
    Int J Colorectal Dis; 2022 Aug; 37(8):1817-1826. PubMed ID: 35835862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease.
    Mahmoud R; Savelkoul EHJ; Mares W; Goetgebuer R; Witteman BJM; de Koning DB; van Tuyl SAC; Minderhoud I; Lutgens MWMD; Akol-Simsek D; van Schaik FDM; Fidder HH; Jansen JM; van Boeckel PGA; Mahmmod N; Horjus-Talabur Horje CS; Römkens TEH; Colombel JF; Hoentjen F; Jharap B; Oldenburg B;
    Clin Gastroenterol Hepatol; 2023 Mar; 21(3):750-760.e4. PubMed ID: 36055567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.